Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition by Goltsov, Alexey et al.
 1 
Compensatory effects in the PI3K/PTEN/AKT signalling network following 
receptor tyrosine kinase inhibition  
 
Alexey Goltsov a*, Dana Faratian b, Simon P Langdon b, James Bown a, Igor Goryaninc and 
David J Harrisonb  
 
a Centre for Research in Informatics and Systems Pathology, University of Abertay Dundee, 
Dundee, DD1 1HG, United Kingdom 
b Edinburgh Breakthrough Research Unit and Division of Pathology, Institute of Genetics and 
Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XR, United Kingdom  
c School of Informatics, University of Edinburgh, Edinburgh, EH8 9AB, United Kingdom  
 
* Corresponding author: Alexey Goltsov 
Address: SIMBIOS, the University of Abertay Dundee, Dundee, DD1 1HG, UK 
Tel: +441382 308471 
E-mail: a.goltsov@abertay.ac.uk 
 
Keywords: HER2 inhibitor; pertuzumab; ERK/PI3K/PTEN/AKT signalling network; 
anticancer drug resistance.  
 
 2 
 
Abstract 
 
Overcoming de novo and acquired resistance to anticancer drugs that target signalling 
networks is a formidable challenge for drug design and effective cancer therapy. 
Understanding the mechanisms by which this resistance arises may offer a route to addressing 
the insensitivity of signalling networks to drug intervention and restore the efficacy of 
anticancer therapy. Extending our recent work identifying PTEN as a key regulator of 
herceptin sensitivity, we present an integrated theoretical and experimental approach to study 
the compensatory mechanisms within the PI3K/PTEN/AKT signalling network that afford 
resistance to receptor tyrosine kinase (RTK) inhibition by anti-HER2 monoclonal antibodies. 
In a computational model representing the dynamics of the signalling network, we define a 
single control parameter that encapsulates the balance of activities of the enzymes involved in 
the PI3K/PTEN/AKT cycle. By varying this control parameter we are able to demonstrate 
both distinct dynamic regimes of behaviour of the signalling network and the transitions 
between those regimes. We demonstrate resistance, sensitivity, and suppression of RTK 
signals by the signalling network. Through model analysis we link the sensitivity-to-
resistance transition to specific compensatory mechanisms within our signalling network. We 
study this transition in detail theoretically by variation of activities of PTEN, PI3K, AKT 
enzymes, and use the results to inform experiments that perturb the signalling network using 
combinatorial inhibition of RTK, PTEN, and PI3K enzymes in human ovarian carcinoma cell 
lines. We find good alignment between theoretical predictions and experimental results. We 
discuss the application of the results to the challenges of hypersensitivity of the signalling 
network to RTK signals, suppression of drug resistance, and efficacy of drug combinations in 
anticancer therapy.  
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1. Introduction 
 
Extensive experimental and theoretical studies of the architecture and dynamics of 
signalling networks (SNs) [1-7] have revealed that the complexity of these networks endows 
cells with marked sensitivity to external receptor signals along with robustness in signal 
transduction and processing [8-10]. This sensitivity provides the cell with a well-defined 
output signal in response to external input stimuli against a background of multiple, parallel 
processes in linked signal cascades, while robustness secures unambiguous concordance 
between output and input signals in the face of perturbations and noise that inevitably occur in 
living processes. This combination of properties arises from the unique protein interactomes, 
self-assembling of signalling protein complexes, protein scaffolding, and multi-level control 
throughout signal transduction from membrane receptors to nucleus. 
The properties of sensitivity and robustness are not determined by any one part of the 
SNs but emerge from the complex, system-scale behaviour of those SN. This emergent 
behaviour thus depends on the interactions among individual components of the SN. The 
functioning of those individual components may be subject to variation due to the external 
environment and/or internal perturbations, and these variations have the potential to impact on 
those emergent properties. While the cell is, in general, resilient to this underlying variation, a 
change in sensitivity and/or robustness may occur as a result of various adaptive processes; 
for example during pathogenesis of disease or acquisition of drug resistance, which itself can 
be regarded as an adaptation process to therapeutic drug intervention [7-13]. 
With particular reference to cancer, acquired and de novo resistance to anticancer drugs 
(also termed cancer robustness) are manifestations of the loss of SN sensitivity to external 
signals [12,13]. Resistance emerges in the case of most effective drugs, including anti-HER2 
monoclonal antibodies trastuzumab and pertuzumab, which inhibit receptor tyrosine kinase 
(RTK) and suppress activation of the PI3K/AKT survival pathway. This resistance causes 
potent cell growth and reduces the impact of treatment on cancer cell mortality in HER2-
dependent breast and ovarian cancers [7,14,15]. Primary sensitivity of tumour cells to these 
drugs may vary dramatically for various cancer cell lines, dependent in part on the expression 
level of the proteins involved in SNs [13]. Many cancers lose original therapeutic 
responsiveness after prolonged treatment and acquire resistance to the RTK inhibitors [13]. 
Various mutations in SNs can cause this resistance, leading to more rapid cancer cell growth 
[11-13]. 
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We hypothesise that sensitivity-to-resistance transition results from compensatory 
features inherent in SNs. We have previously shown that the tumour suppressor PTEN 
involved in PI3K/PTEN/AKT signalling network plays a key role in resistance to RTK 
inhibition [7]. Here we extend with inclusion of additional mechanisms our approach in [7] to 
study in detail the signalling network behaviour relating to drug resistance acquisition, with a 
focus on identifying the compensatory features of the PTEN/PI3K/AKT pathway.  In 
particular, we explore the observed effect of PTEN on drug resistance [7] within the broader 
context of compensatory mechanisms emerging in this SN as a result of sensitivity-to-
resistance transition. 
More generally, both experimental and theoretical studies have revealed several system-
scale properties of SNs which can provide such compensatory mechanisms, including (i) 
redundancy and multiple cross-talk in SN topology, affording alternate pathways to effect a 
particular behaviour [1,12,13,16]; (ii) gene/metabolic feedback control loops due to 
combinations of activation and inhibition/repression processes, regulating cell response to 
perturbation [8]; and (iii) mutations of the drug targets leading to acquired resistance in 
phenotypes under particular drug regimes [8,11,12].   
Here, we focus on another compensatory mechanism typical in SNs, made possible due 
to specific components present in almost all cellular SNs, for example, in MAP kinase 
pathways: signalling cycles composed of two inter-convertible enzymes, kinases and 
phosphatases.  Numerous theoretical and experimental studies of the dynamic properties of 
these cycles have revealed a wide spectrum of the different modes of cycle functioning, such 
as toggle switch, amplification, ultrasensitivity, signal transduction, and oscillation [17-22], 
which are realised by different sets of kinetic parameters of individual enzymes involved in 
SNs. Also experimental and clinical research has shown that aberrant expression and 
mutations of the enzymes making up those cycles cause cancer development and resistance to 
anticancer drugs [13].  We suggest that mutations of the enzymes involved in the signalling 
cycles can cause the transitions among these modes and some of these modes may underlie 
compensatory mechanisms for drug intervention.     
We present a systems biology approach to elucidate the connection between the kinetic 
properties of the PI3K/PTEN kinase-phosphatase signalling cycle and the response of the 
whole ERK/PI3K/PTEN/AKT pathway to RTK stimuli. Using both computational and 
experimental methods we studied the compensatory mechanisms within the PI3K/PTEN/AKT 
signalling pathway that determine the change in sensitivity of AKT activation to RTK 
inhibition in ovarian cancer cells. In our theoretical work we defined this signalling pathway 
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using kinetic modelling, and sensitivity of the SN to RTK inhibitor (pertuzumab) was 
investigated by perturbing the PI3K/PTEN/AKT signalling cycle. The balance among these 
enzyme activities was encapsulated within a control parameter that integrates the functional 
properties of multiple SN components. We then varied this control parameter, effecting a 
combination of perturbations to the relevant component properties, to represent different 
mutations and the impact of external inhibitors. The perturbation technique we describe 
allowed us to vary the SN dynamics from high to low sensitivity to RTK signals and to 
explore the sensitivity-to-resistance transition. We also perturbed the signalling pathway 
experimentally to test theoretical model predictions. 
  
2. Materials and methods 
 
2.1. Computational methods 
 
A study of the compensatory properties of the SN against RTK inhibitor is based on an 
application of the computational model of RAF/MEK/ERK and PI3K/PTEN/AKT signalling 
developed in [7]. The model, its extension, and computational methods are outlined in section 
2.1.1. In Section 2.1.2 we provide the method of derivation of the control parameter, which is 
based on the analytical analysis of a subsystem of the SN – the PI3K/PTEN/AKT signalling 
cycle. 
 
2.1.1. Signalling network model  
 
To study the compensatory properties of the SN we built upon our existing kinetic 
model of RAF/MEK/ERK and PI3K/PTEN/AKT signalling [7]. This model describes the 
response kinetics of the SN to heregulin (HRG)-induced HER3/HER2 receptor 
heterodimerisation and the effect of RTK inhibitor, pertuzumab (2C4 antibody) [14,15] on 
ERK and AKT activation in the human ovarian carcinoma cell line PE04 [7]. The scheme of 
the signalling network that corresponds to the model is shown in Fig. 1. In the current model 
we omitted the formation of HER3/HER4, HER4/HER4, and HER2/HER4 receptor 
complexes because HER4 receptor expression was barely detectable in PE04 cell line [7]. To 
model the effect of perturbation of the PI3K/PTEN/AKT signalling cycle on the whole SN, 
we added to the model [7] the reaction of inhibition of PI3K enzyme (see Fig. 1).  
The developed model was parameterised on the basis of the experimental data on 
phosphorylation kinetics of HER2, ERK, AKT, and PTEN in the absence and presence of 
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pertuzumab [7]. Figs. 2A and 2C show agreement between theoretical and experimental data 
on the phosphorylation kinetics of pHER2 and pAKT. Computational modelling of the SN 
was performed using the DBSolve package for kinetic modelling [23] and SimBiology 
modelling software (MATLAB, The MathWorks Inc.). The review of kinetic modelling 
approach used in the work is given in [24]. 
 
 
2.1.2. Control parameter derivation  
 
To derive the control parameter of the PI3K/PTEN/AKT signalling pathway we 
analysed analytically the kinetic properties of the key subsystem of the whole SN – the 
PI3K/PTEN/AKT signalling cycle (see subsystem framed in Fig. 1). This cycle consists of 
two inter-convertible enzymes, phosphoinositide 3-kinase, PI3K, and phosphatase, PTEN 
(tensin homolog deleted on chromosome 10), as well as the protein kinase, AKT. PI3K 
enzyme converts phosphatidylinositol (PIP2) to phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), and in turn PTEN dephosphorylates PIP3 and recycles the process [25]. The 
consumption of PIP2 and the production of the active complex AKT-PIP3 in the cycle are 
determined by the relationship between the activities of these enzymes.  
To define the control parameter characterising the dynamics of the PI3K/PTEN/AKT 
cycle we considered its kinetic model and studied the steady state of this subsystem. The 
model includes the following reactions of the whole SN kinetic model [7] (see subsystem 
framed in Fig. 1): 
, 31
1
3 :   PIP2+PI3K* PI3K*-PIP2 PI3K*+PIP3;
cat PI Kkk
PI K
k
V
−
→↔      (1) 
,2
2
,
:    PIP3+PTEN PTEN-PIP3 PTEN+PIP2;
cat PTENkk
PTEN l
k
V
−
→↔      (2) 
3
3
:     PIP3+AKT AKT-PIP3.
k
AKT
k
V
−
↔         (3) 
Analysing the steady state of the systems of ordinary differential equations (ODEs) 
corresponding to the model (1)-(3) (see Appendix), one can derive a relationship between the 
steady state concentrations of the substrate, PIP2s, the end product, AKT-PIP3s, of the cycle 
and the enzymes, *sPI3K , PTENs as: 
, 3 , ,
*
, 3 ,
1 12
3 - 3
m PI K cat PTEN s d AKT
s
cat PI K s m PTEN o s o
K k PTEN K
PIP
k PI K K AKT AKT PIP AKT
 
= − 
 
,   (4) 
 7 
where Km,i, kcat,i, Kd,i=k-i/ki – Michaelis, catalytic, and dissociation constants; ki and k-i – 
reaction rate constants of forward and reverse reactions (1)-(3). 
For an approximate analysis of equation (4), we assume that the steady state 
concentrations of the PTENs and *sPI3K  enzymes differ slightly from their initial 
concentrations, PTENo, PI3Ko [5] and determine a dimensionless parameter Γ equal to the 
relation of the left hand of equation (4): 
, 3 , ,
, 3 , 33
m PI K cat PTEN o d AKT PTEN
cat PI K o m PTEN o PI K AKT
K k PTEN K v
k PI K K AKT v v
Γ = = .   (5) 
The parameter Γ determines the balance of the enzyme activities of PTEN, PI3K*, and 
AKT: vPTEN , vPI3K , and vAKT , where 
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Determined on the basis of the PI3K/PTEN/AKT cycle dynamics, Γ was used to study 
the response kinetics of the whole SN to RTK activation and inhibition. It is clear that the 
complex dynamics of the large-scale signal transduction system cannot be described 
completely by a single parameter, but we suggest that some key features of its functioning 
may be controlled by the abstracted parameter Γ. Note that a similar parameter was 
introduced by Ventura et al. [22] to analyse the dynamics of separate 
phosphorylation/dephosphorylation cycles and their cascades in MAPK pathway. 
Γ can be changed as a result of the following cellular processes: 1) enzyme inhibition 
causing a decrease in the effective concentration of enzyme, unbound with inhibitor; 2) 
variation in enzyme expression level leading to changes in enzyme concentration; and 3) 
enzyme mutations resulting in possible alterations of the catalytic constant, kcat and/or enzyme 
affinity to the substrate, Kd (or Michaelis constant, Km). Throughout our analyses, we use the 
normalized parameter γ where γ=Γ/Γo. The value of Γo corresponds to the reference enzyme 
activities of PTEN, PI3K, and AKT used in the modelling of pertuzumab effect [7] (Γo 
=3·104). This allows us to explore the relative impact of proportional changes in γ, with γ=1 
corresponding to a normal response to RTK inhibition. Note that the control parameter γ is the 
extension of the resistance factor [7], which considers the balance of the activities only of two 
enzymes: PI3K and PTEN. 
2.2. Experimental methods 
 
2.2.1. Cell Culture and Collection of Lysates 
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PE04 cells were routinely grown as monolayer cultures in DMEM supplemented with 
10% heat-inactivated fetal calf serum (FCS) and penicillin / streptomycin (100IU/mL) in a 
humidified atmosphere of 5% CO2 at 37ºc. Time course experiments were set up by plating 
cells into 10cm petri dishes, which were then left for 48 h. Cells were washed briefly in PBS 
before transfer to phenol red-free DMEM containing 5% double charcoal-stripped serum 
supplemented with penicillin/streptomycin (100 IU/mL) and glutamine (0.3 mg/mL) for a 
further 48 h prior to treatment to ensure estrogen free conditions. Paired lysates were prepared 
by first treating relevant dishes with pertuzumab (100 nmol/L) +/- bpV(pic) (50 nmol/L) +/- 
LY294002 (5 µmol/L) immediately followed by the addition of heregulin-β (1 nmol/L). 
Samples were collected at time points of 1, 2, 5, 10, 30, and 60 min for dynamic time course 
profiles, or 60 min for static measurements, washed in PBS, and immediately lysed in ice-
cold isotonic lysis buffer [50 mM Tris-HCl (pH 7.5), 5 mM EGTA (pH 8.5), 150 mM NaCl, 
1% Triton X-100] supplemented with aprotinin (10 µg/mL) and a protease inhibitor cocktail 
(Roche, 11836153001). Lysates were centrifuged for 6 min at 13,000 x g and protein 
concentrations of supernatants subsequently determined using the BCA assay (Sigma, BCA-
1).  
 
Western Blotting  
Protein lysates were electrophoretically resolved on either 10% or 12% SDS-PAGE and 
transferred overnight onto Immobilon-P membranes (Millipore, Bedford, MA). After transfer, 
membranes were blocked with 1% blocking agent (Roche, #1520709) in TBS before probing 
overnight at 4˚C with the appropriate primary antibody made up in 0.5% blocking agent. 
Primary antibodies used for western blotting were as follows: anti-phospho-AKT (Ser473) 
(Cell Signaling Technology, #9271) at 1:1000; anti-AKT (Cell Signaling Technology, #9272) 
at 1:1000; anti-phospho-p44/42 MAP Kinase (Thr202/Tyr204) (Cell Signaling Technology, 
#9101) at 1:1000; anti-p44/42 MAP Kinase (Thr202/Tyr204) (Cell Signaling Technology, 
#9102) at 1:1000; anti-HER1 (Cell Signaling Technology, #2232) at 1:1000; anti-HER2 (Cell 
Signaling Technology, #2242) at 1:1000; anti-HER3 (Cell Signaling Technology, #4754) at 
1:1000; anti-HER4 (Cell Signaling Technology, #4795) at 1:1000; anti-PTEN (Cell Signaling 
Technology, #9552) at 1:1000; anti-phospho-PTEN (Ser370) (Upstate, #07-889) at 1:1000. 
Immunoreactive bands were detected using enhanced chemiluminescent reagents (Roche, 
1520709) and Hyperfilm ECL film (GE Healthcare, UK). Bands were scanned using an Epson 
Perfection 4990 scanner and Integrated Optical Density (IOD) absorbance values were 
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obtained by densitometric analysis using Labworks gel analysis software (UVP Life Sciences, 
Cambridge, UK). 
 
3. Results 
 
3.1. The effect of γ on signalling response to RTK inhibition  
 
We focussed on the sensitivity of the AKT response as a surrogate readout of the SN to 
changes in the control parameter of PI3K/PTEN/AKT signalling cycle, γ. To analyse the 
dependence of AKT activation on γ we compared the theoretical response kinetics of the 
system to inhibition of input signal, pHER2, simulated at different values of γ, where this 
input signal is both independent on γ and agrees with experimental data (see Fig. 2A). The 
system response at γ=1 showed that 90% inhibition of pHER2 resulted in approximately 90% 
and 80% inhibition effect on PI3K and AKT activation respectively at 60 min after HRG 
stimulation (see Figs. 2B and 2C). 
In our model formulation, decreasing γ had no impact on the response of PI3K 
activation, as γ controls the downstream PI3K/PTEN/AKT cycle kinetics (the results shown in 
Fig. 2B are independent of γ). However, the output signal pAKT was sensitive to the value of 
γ. Fig. 2D shows the kinetics of the pAKT signal in the absence and presence of pertuzumab 
calculated for a low value of γ; γ=0.5. As can be seen from Fig. 2D there is a loss in 
sensitivity to treatment, with no inhibition effect from 100 nM pertuzumab on pAKT signal 
under this condition: the concentration of pAKT remains unchanged in the presence of 
pertuzumab after 30 min of HRG stimulation. Thus, in contrast to the case where γ=1 (Fig. 
2C), the inhibition of RTK and PI3K (Figs. 2A and 2B) does not cause inhibition of the pAKT 
signal (Fig. 2D). This kinetics may be explained by amplification of a small, inhibited RTK 
signal into a maximal output signal, pAKT, by the PI3K/PTEN/AKT cycle at low values of γ. 
Below we analyse this amplification regime of the signalling cycle. 
To show in detail how the PI3K/PTEN/AKT cycle controls the level of output signal, 
pAKT, we have calculated the consumption kinetics of PIP2, for the different pHER2 signals 
at γ=1
 
and 0.5 (see Figs. 2E and 2F). As can be seen, the steady state concentration of PIP2 
depends on pertuzumab presence as well as γ. When γ=1, the steady state concentration of 
PIP2 differs in the absence and presence of pertuzumab (see Fig. 2E). This difference of the 
two signals translates into a difference in AKT activation signals (see Fig. 2C). In contrast, at 
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γ=0.5 there is little distinction between PIP2 concentrations in the absence and presence of 
pertuzumab after 30 min of HRG stimulation (see Fig. 2F). This small difference does not 
lead to a system-scale difference between the two final pAKT signals, despite the presence of 
RTK inhibitor (see Fig. 2D). Note that in the model we do not consider cellular metabolism of 
PIP2 [26] and its effect on the signalling, neglecting de novo synthesis and membrane 
diffusion of PIP2 during signal generation. 
This result shows interconnection between γ and the compensatory properties of the 
PI3K/PTEN/AKT signalling network against inhibition of receptor signal. This compensatory 
mechanism thus confers insensitivity of AKT activation signal to inhibition of receptor 
stimuli. This compensatory effect on the reduction of γ results from the transition of the 
system from sensitivity to resistance regime, which in itself arises from the perturbation of the 
balance among enzyme activities in the PI3K/PTEN/AKT cycle. 
To analyse this effect we calculated the pAKT dose-dependence on pertuzumab 
concentration for different values of γ (see Fig. 3). The black line in Fig. 3 presents the pAKT 
dose-dependence calculated for the reference case γ=1. According to this result, the obtained 
value of pertuzumab IC50 is equal to 40 nM, in agreement with known experimental data [7]. 
To model the pAKT dose-dependence at γ<1 we have taken into account in the model the 
inhibition of PTEN enzyme by the bpV(pic) inhibitor [27]. PTEN inhibition leads to a 
decrease in γ to γ<1 due to a fall in the effective concentration of enzymes, unbound with 
inhibitor. Note that we demonstrate below that both PI3K and AKT activities may also be 
varied to change γ. The results of the calculation showed that the pAKT dose-dependence at 
γ<1 (blue line in Fig. 3) is transformed to a higher pertuzumab concentrations (IC50=1 µM). 
This leads to resistance of AKT activation at pertuzumab concentrations in the region of the 
typical IC50 (40 nM) for this drug. 
The theoretical prediction of the resistance acquisition against RTK inhibition at the loss 
of PTEN activity has been confirmed by experiment with PTEN inhibition by the bpV(pic) 
inhibitor [7]. Fig. 4 shows a comparison of the theoretical and experimental data on 
phosphorylated AKT concentration observed at 30 min after HRG activation of the human 
ovarian carcinoma cell line PE04 at different combinations of inhibitors. Bars 3 show an 
inhibition effect of pertuzumab on AKT phosphorylation. The inhibition of PTEN by 
bpV(pic) leads to compensation for pertuzumab action (see bars 5 in Fig. 4) and restores the 
initial level of HGR-activated AKT signal (see bars 2 in Fig. 4). Note that PTEN inhibitor 
bpV(pic) does not influence AKT activation when added alone (see bars 8 in Fig. 4). Thus the 
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change of the systems parameter of the PI3K/PTEN /AKT cycle, γ, as a result of PTEN 
inhibition, leads to the sensitivity-to-resistance transition in the SN response to RTK 
inhibition. 
 
3.2. Analysis of the sensitivity-to-resistance transition 
 
To study the sensitivity-to-resistance transition in the PI3K/PTEN/AKT pathway in 
detail, we calculated the dependence of the output signal, pAKT(pHER2,γ), on the input 
signal, pHER2 for different values of γ (see Fig. 5). The amplitude of the pHER2 signal was 
varied by changing HER2 inhibitor concentration and this amplitude was normalised to the 
maximal value of the pHER2 signal in the absence of pertuzumab. The different values of γ 
correspond to different initial concentrations of PTEN enzyme, while the activities of PI3K 
and AKT are assumed constant (see equation (5)). Below we also show that a similar 
dependence, pAKT(pHER2,γ), may be obtained by likewise varying PI3K or AKT enzyme 
activities.  
The smooth dependence pAKT(pHER2,γ) at the values of γ ≅ 1 shows that the 
signalling system was sensitive with respect to the level of input signal, that is the output 
pAKT signal was nonlinearly proportional to the input signal, pHER2 (see line 6 in Fig. 5). In 
this sensitivity regime the PI3K/PTEN/AKT cycle functions as a discriminator of the receptor 
signal, i.e. under this condition, inhibition of HER2 receptor caused a corresponding 
inhibition of pAKT signal. 
When γ<1, as a result of the loss of PTEN activity (see equation (5)), there was a 
dramatic change in the PI3K/PTEN/AKT cycle behaviour (see lines 1-5 corresponding to 
γ<1 in Fig. 5). At these values of γ the cycle switches to hypersensitivity (amplification) mode 
with near zero-order kinetics [17,18]. Beginning with a definite threshold of pHER2, the 
system amplifies the input pHER2 signals up to the maximal output pAKT signal. In this 
case, the lower the value of γ, the weaker the ΗΕR2 signal that is amplified. In this regime, 
the signalling network response becomes insensitive to the level of external signals, i.e., the 
output signal does not depend on the input signal for a wide range of pHER2 values (for 
example, from 0.05 to 1 at γ=0.5, see line 2 in Fig. 5). We suggest that this amplification 
regime corresponds to resistance of pAKT response to RTK inhibition and the transition from 
sensitivity to resistance regime represents a compensatory mechanism of the SN.  
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The increase in γ to values higher than 1 caused suppression of pAKT signal, relative to 
the reference point γ=1, everywhere over the region of pHER2 signal values (see line 7 
corresponding to γ>1 in Fig. 5). In this region of γ, the PI3K/PTEN/AKT cycle inhibits pAKT 
signalling response and switches to suppression mode. 
The sensitivity-to-resistance transition was also observed when changes in γ represent 
variation in PI3K or AKT enzyme activity with constant activities of both PTEN and AKT or 
PI3K respectively. Supplementary Fig. 1 shows the dependence of pAKT(pHER2,γ) when γ 
changes due to variation of dissociation constants of PI3K and AKT enzymes. According to 
the definition of γ (see equation (5)), increasing PI3K activity through decreasing of the 
dissociation constant of PI3K, Kd,PI3K, leads to a decrease in γ and therefore to the sensitivity-
to-resistance transition in the SN. Supplementary Fig. 1A shows that pHER2 signals higher 
than 0.2 are amplified up to the maximal pAKT signal. The similar behaviour in the 
dependences of pAKT(pHER2,γ) was observed in the model at the decrease in control 
parameter γ due to the increase of the dissociation constant of AKT, Kd,AKT (see Supplementary 
Fig. 1B).  
Using these results, and to explore the impact of changes in activities of PTEN, PI3K 
and AKT on resistance of the SN, we defined the resistance index R (as in [7]) of the SN as 
the value of the pAKT signal at a specified level of the RTK inhibition. Choosing 90% 
inhibition of the pHER2 signal (see Fig. 2A) we introduced the resistance index, R90, as the 
ratio R90 = pAKT90/pAKT0, where pAKT90 is the value of the pAKT signal where 90% of the 
pHER2 signal is inhibited and pAKT0 is the pAKT signal in the absence of RTK inhibition. 
R90 reflects the change in responsiveness, or resistance, of the SN to the inhibition of receptor 
signals. Fig. 6 shows the theoretical dependence of the resistance index R90(γ) on γ, where 
γ was varied by changing PTEN, PI3K or AKT enzyme activities. Loss of PTEN activity 
exerted the most pronounced effect on the resistance index R90(γ) (black line in Fig. 6). 
Maximal resistance, when R90 ≅1, means that 90% inhibition of RTK causes no 
inhibition of the pAKT signal. When γ was varied through loss of PTEN activity, the maximal 
resistance index R90(γ) was observed at γ<0.6. In this region of γ, the PI3K/PTEN/AKT cycle 
amplifies the inhibited RTK signals up to the maximal value and thereby compensates for 
inhibition of the input signals. Thus, at these values of γ the SN manifests resistance against 
HER2 inhibition. On increasing γ, the resistance index R90(γ) decreased, and the resistance-to-
sensitivity transition occurred. In the region γ≅1, the SN was sensitive to input signals: 90% 
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RTK inhibition causing ~80% inhibition of the pAKT signal (R90(γ=1)=0.2). Variation of 
PI3K and AKT activities exerted a weaker influence on the resistance index R90(γ) (see blue 
and red lines in Fig. 6). 
The sharp transition in R90(γ) on varying PTEN activity arises from post-translational 
regulation of PTEN (see black line in Fig. 6). It is known that activation of PTEN is 
controlled by the phosphorylation/dephosphorylation cycle, where the phosphorylated form of 
PTEN is inactive [25]. In our model of PTEN [7] we have taken into account the PTEN 
phosphorylation/dephosphorylation cycle (see PTEN/pPTEN cycle in Fig. 1), with the 
phosphorylation reaction phenomenologically describing phosphorylation of PTEN by casein 
kinase 2 (CK2) and glycogen synthase kinase 3β (GSK3) [25]. As it is unknown which 
enzyme dephosphorylates PTEN [25], we assumed a weak protein phosphatase activity of 
PTEN [7] and its auto-dephosphorylation properties [25]. Our calculation showed the 
important role of the PTEN/pPTEN cycle in the regulation of the PI3K/PTEN/AKT cycle. 
The deletion of this cycle from the model resulted in the disappearance of the sharp transition 
in the resistance index dependence, R90(γ) (see dashed black line in Fig. 6), and the resistance 
index dependence was more similar to the cases corresponding to changes in γ due to PI3K 
and AKT activity variations (blue and red lines in Fig. 6). The impact of the PTEN/pPTEN 
cycle on the PI3K/PTEN/AKT cycle behavior underlies the irregularities in the function 
pAKT(pHER2,γ) visible in Fig. 5. This threshold transition from sensitivity to resistance at 
the decrease of PTEN activity results from additional inactivation of PTEN due to its 
phosphorylation by CK2 and GSK3, which in turn causes the decrease of γ.  
γ>1 leads to a decrease in the resistance index R90(γ), meaning that the 
PI3K/PTEN/AKT cycle causes additional suppression of the inhibited RTK signal 
(corresponding to the suppression region at γ>1 in Fig. 6). High values of γ can be observed in 
cells in response to increasing of PTEN activity due to gene amplification [12], or the 
decreasing of PI3K activity at its inhibition [28], or the reduction in AKT activity as a result 
of its inhibition or mutation [29]. 
 
 
 
 
3.3. The effects of combination inhibition on the sensitivity-to-resistance transition 
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The combined effect of RTK and PTEN inhibitors (pertuzumab and bpV(pic), 
respectively) discussed in section 3.1 showed that PTEN inhibition abrogates the inhibition 
effect of pertuzumab. Here, the additional effect of the PI3K inhibitor, LY294002 [28] is 
considered individually and then in combination with RTK and PTEN inhibitors (Fig. 1).  
First, we calculated pAKT dose-dependence on LY294002 concentration (see black line 
in Fig. 7). At the concentration of LY294002 near its IC50 (4 µM) the effective concentration 
of PI3K* active form reduces by a factor of six (data are not shown), leading to γ increasing 
from 1 to 6, and the PTEN/PI3K/AKT cycle to function in the suppression regime. The 
experimental measurement of pAKT inhibition confirms the model prediction of 60% pAKT 
inhibition at 5 µM of LY294002 at 30 min after HRG stimulation (see bars 7 in Fig. 4 and the 
point at the black line in Fig. 7). 
Second, we considered the combined effect of PTEN and PI3K inhibition on pAKT 
dose-dependence. As can be seen in the definition of γ (5), the inhibition of PTEN and PI3K 
affects the parameter γ in opposite directions: that is PTEN inhibition causes a decrease in γ 
and a move of the SN function to the resistance region; and PI3K inhibition leads to an 
increase in γ that shifts the system into the suppression region. We calculated the pAKT dose-
dependence on LY294002 concentration in the presence of PTEN inhibitor, bpV(pic) (see 
dotted line in Fig. 7). The action of bpV(pic) causes a shift of the pAKT dose-dependence to 
higher concentrations of LY294002 relative to that calculated for the PI3K inhibitor alone 
(solid line in Fig. 7). Thus, PTEN inhibition leads to suppression of the PI3K inhibitor action 
in the wide concentration range near the IC50 of LY294002. Here, PTEN inhibition 
compensates for pAKT signal inhibition by PI3K inhibitor, and the PTEN inhibitor plays an 
antagonist role against the PI3K inhibitor. This PTEN-induced resistance to PI3K inhibition is 
similar to PTEN-induced resistance to RTK inhibition discussed in section 3.1. Note, that the 
theoretically obtained ten times shift of IC50 together with the change in shape of the pAKT 
dose-dependence for LY294002 at PTEN inhibition by bpV(pic) (see Fig. 7) is in agreement 
with experimental data [27].  
We next considered the effect of another combination of two inhibitors: PI3K inhibitor, 
LY294002, and RTK inhibitor, pertuzumab (see scheme in Fig. 1). Fig. 3 shows the 
theoretical pAKT dose-dependence for pertuzumab in the presence of LY924002 (green line). 
As can be seen, PI3K inhibitor leads to a shift of the dose-dependence and pertuzumab IC50 
towards lower concentrations of pertuzumab relative to that calculated for pertuzumab alone 
(black line in Fig. 3). Thus, the PI3K inhibitor is synergistic when combined with the RTK 
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inhibitor. The increase in γ resulting from the PI3K inhibition (see equation (5)) causes the SN 
transition towards the suppression regime.   
Summarising the effect of γ on AKT activation, Fig. 3 shows the pAKT dose-
dependences for the RTK inhibitor (pertuzumab), calculated at different values of the 
parameter γ: γ=1 (pertuzumab alone, black line); γ<1 (pertuzumab + bpV(pic), blue line); and 
γ>1 (pertuzumab+ LY294002, green line). The observed shifts of the pertuzumab IC50 confirm 
the effect of each inhibitor on γ and the behaviour of the PTEN/PI3K/AKT cycle.  
In addition to these pairwise effects, we considered the effect of both inhibitors 
LY294002 and bpV(pic) on RTK inhibition. As discussed above, the loss of PTEN activity as 
a result of PTEN inhibition by bpV(pic) leads to compensation for the effect of RTK 
inhibition by pertuzumab (see blue line in Fig. 3). This compensation effect is due to the 
sensitivity-to-resistance transition occurring when γ<1. The additional inhibition of PI3K in 
this case will cause γ to return to the initial value γ≅1. We hypothesised this restores 
responsiveness to RTK inhibition by reversing the sensitivity-to-resistance transition. 
To verify this we calculated the pAKT dose-dependence for pertuzumab in combination 
with LY294002+bpV(pic) (see red line in Fig. 3). As can be seen, the addition of PI3K 
inhibitor causes a shift in the pAKT dose-dependences calculated at PTEN inhibition to the 
position close to the dose-dependences obtained for pertuzumab alone (black line in Fig. 3). 
The approximate matching of the two dose-dependencies simulated without/with 
LY294002+bpV(pic) combination (black and red lines) confirms that PI3K and PTEN 
inhibitors compensate for one another at γ≅1. 
To test the model predictions experimentally, we have ascertained the effects of 
LY294002 alone and the LY294002+bpV(pic) combination on pertuzumab inhibition in the 
ovarian cancer cell line PE04. The measurements were performed at the inhibitor 
concentrations corresponding to the character points given at the theoretical dose-dependence 
curves (see Figs. 3 and 7). Comparison of the theoretical and experimental results is shown in 
Fig. 4. Bars 6 depict the combined effect of LY294002 and bpV(pic) on pertuzumab action. 
The experimental data confirms the predicted effect of mutual compensation for two inhibitor 
action, LY294002 and bpV(pic) and restoration of pertuzumab inhibition. The comparison of 
inhibition effects of LY294002 alone (bars 7) and in combination with pertuzumab (bars 4) 
shows the synergetic action of RTK and PI3K inhibitors, as predicted in the model.  
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The comparison of the overall theoretical and experimental data depicted in Fig. 4 
shows that the proposed model of SN response control [7] describes satisfactorily the 
individual effects of three inhibitors as well as their combination actions.   
 
Discussion 
 
A systems biology approach was employed to study the compensatory mechanisms 
underlying the observed counteraction of the signalling network to inhibition of RTK in 
human cancer cell lines. We focussed on the compensatory mechanisms arising from the 
functioning of a key building block involved in the PI3K/AKT signalling pathway – the 
PI3K/PTEN/AKT cycle. This cycle, and the enzymes involved in it, have been found to play a 
crucial role both in tumorigenesis and acquisition of resistance to cancer therapy [1,13,29-38]. 
Using kinetic modelling, combined with experimentation, we showed that the 
PI3K/PTEN/AKT cycle can implement a compensatory mechanism against RTK inhibition. 
The results indicated that the system-level properties of the whole SN depend upon the 
balance among activities of the enzymes involved in the PI3K/PTEN/AKT cycle. 
To explore these properties, we introduced a control parameter γ, encapsulating the ratio 
of the enzyme activities vPTEN:vPI3K:vAKT (see equation (5)) and studied the response of the 
whole system to heregulin-induced activation and RTK inhibition at different values of γ. The 
results of the modelling showed that the SN can function in three different modes and 
transition between these modes can occur by varying γ: 1) sensitivity (γ≅1), 2) resistance 
(γ<1), and 3) suppression (γ>1). In sensitivity mode inhibition of the input signal, pHER2, 
caused inhibition of the output signal, pAKT. In resistance mode the system is robust to RTK 
inhibition, since this inhibition does not influence the saturated level of AKT activation in a 
wide physiological range of inhibitor concentrations. In suppression mode, the system was 
found to inhibit receptor signals.  
The introduction of γ permits the analysis, in a unified fashion, of the effects of enzyme 
activity imbalance in the PI3K/PTEN/AKT cycle which could be caused by possible 
mutations and/or inhibition of the enzymes involved. We considered loss of PTEN activity, 
observed in various cancer types due to PTEN mutation [13,32-34] and shown to contribute to 
the acquired resistance to RTK inhibitors [7,33]. Both the theoretical and experimental results 
obtained confirmed that loss of PTEN activity, leading to a decrease in γ, induces the 
sensitivity-to-resistance transition and causes resistance to RTK inhibition [7]. We also 
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considered the effect of changing γ as a result of a kinetic property variation of PI3K enzyme 
as well as its inhibition by LY294002. The mutations of PIK3CA gene leading to the catalytic 
activation of PI3K have been found to occur in different types of cancer [35-37] and also to 
introduce resistance to RTK inhibition [13]. Modelling showed that activation of PI3K 
enzyme due to an increase in its affinity to substrate leads to an increase in γ and moves the 
SN response into the resistance region. Likewise, the effect of a rise of AKT enzyme activity 
on imbalance in the PI3K/PTEN/AKT cycle was modelled. The increasing of AKT affinity to 
the lipid second messenger, PIP3 decreases γ and switches the system function into the 
resistance mode. Such perturbation of the PI3K/PTEN/AKT cycle as a result of AKT 
overproduction and aberration in its expression were observed in different types of cancer 
[13,29,38,39].  
As an illustration of the key role of γ in the resistance of the SN to RTK inhibition we 
represent in Fig. 8 our experimental data on the correlation between γ and the inhibition of 
growth rate of 13 ovarian carcinoma cell lines [7]. Here, γ was estimated based on Western 
Blotting data on the total concentrations of PTEN, PI3K, and AKT enzymes as well as the 
assessment of the four most common mutations in the PIK3CA gene [7,37]. These mutations 
were assumed to increase the activity of PI3K twofold [38]. As the kinetic properties of these 
enzymes as well as the expression status of other proteins involved in the SN were not 
considered in the calculation, this result has to be regarded as an approximation. Despite this, 
the obtained dependence demonstrates a notable correlation between the balance of enzyme 
activities in PI3K/PTEN/AKT cycle and the inhibition of growth rate for various ovarian 
cancer cell lines. This shows that γ may be a useful indicator in determining the efficacy of 
pertuzumab for distinct cancer cell lines.  
The results of the modelling demonstrate that it is possible to reverse resistance-to-
sensitivity transition by changing γ. Resistance against receptor inhibition can be aborted for a 
certain range of RTK inhibitor concentration by external perturbation of the PI3K/PTEN/AKT 
cycle. To study this, we simulated the effects of combinations of two and three inhibitors and 
carried out complementary experiments on combination inhibition of HRG-induced activation 
of human ovarian carcinoma cell line PE04. Results show that resistance against RTK 
inhibition acquired as a result of the partial loss of PTEN activity (γ<1) may be restored by 
increasing γ up to 1, e.g. due to PI3K inhibition (see red line in Fig. 3). We propose that this 
effect is observed in the case of cancer cells with PTEN mutation because of the non-zero 
level expression of PTEN detected in these cancer cells [40]. We demonstrate that 
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perturbation of the enzyme activity balance in the PI3K/PTEN/AKT cycle is likely to be 
responsible for both cancer development (robust tumour growth) and acquired and de novo 
resistance against RTK inhibition (cancer robustness). The most pronounced effect on 
resistance was loss of PTEN activity, and this is determined by the interaction between 
PI3K/PTEN/AKT cycle and post-translation regulation of PTEN activity in the PTEN/pPTEN 
cycle, governed by CK2/GSK3 enzymes as well as auto-dephosphorylation activity of PTEN 
[25].  
From our investigations into the combined action of inhibitors, we propose that targeting 
different enzymes involved in compensatory loops is a promising approach to prevent and 
suppress resistance against RTK inhibition. Consequently, combined theoretical and 
experimental studies of the compensatory mechanisms of the SN against external 
perturbations may inform development of effective combination cancer therapy [41].  
 
Conclusions 
 
We developed a computational and experimental approach to dissect the compensatory 
mechanisms underlying resistance of the PI3K/PTEN/AKT signalling network to RTK 
inhibition. We demonstrated that the compensatory properties of the SN may be characterised 
by a system-level control parameter, γ (generalised resistance factor [7]), which may be 
estimated experimentally from protein abundance and enzyme kinetic property data. 
We studied the compensatory loops involving PTEN, PI3K, AKT, and CK2/GSK3 
enzymes arranged in individual modules of a large-scale RAF/ERK/PI3K/AKT signalling 
network. This study highlighted the key role of PTEN in the compensatory response of the SN 
in the transition from sensitivity to resistance to RTK inhibition in combination treatment 
regimes [7]. 
More broadly, we have shown a generalisable and scalable approach to support further 
unravelling of the compensatory loops including other enzymes and subsystem motifs of SNs 
to address drug resistance [42]. Moreover, the approach proposed here may be used to inform 
the identification of therapeutic biomarkers. This is made possible by the systematic 
manipulation of signalling network dynamics through key control parameters that govern the 
dynamics of the whole signalling network combined with a mechanistic interpretation of that 
manipulation, enabling model exploration to inform directly the drug discovery process. 
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Appendix 
 
The system ODEs corresponding to submodel of PI3K/PTEN/AKT cycle (see framed 
module in Fig. 1 and reactions (1)-(3)) is represented in the form 
KPIcatVVVdt
dPIP
3,11
2
++−=
−
 
(A1) 
KPIcatVVVdt
KdPI
3,11
*3
++−=
−
 
(A5) 
333,22
3
−−
+−++−= VVVVV
dt
dPIP
KPIcat  
(A2) 
PTENcatVVVdt
dPTEN
,22 ++−= −  
(A6) 
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23
−+−=
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,22
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33
3
−
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dt
PIPdAKT -
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(A8) 
where the reaction rates Vi are defined by the following rate equations in action mass 
approximation  
2*311 PIPKPIkV ⋅⋅=  PTENPIPkV ⋅⋅= 322  AKTPIPkV ⋅⋅= 333  
2311 PIPKPIkV -⋅= −−  322 PIPPTENkV -⋅= −−  333 PIPAKTkV -⋅= −−  
233,3, PIPKPIkV KPIcatKPIcat -⋅=  3,, PIPPTENkV PTENcatPTENcat -⋅=   
 For system (A1)-(A8) the following conservation lows occur  
* *
- 3 ;  3 3 - 2 3 ;   - 3
2 3 - 3 3 - 2 - 3 2
o o o
o
AKT AKT PIP AKT PI K PI K PIP PI K PTEN PTEN PIP PTEN
PIP PIP AKT PIP PI K PIP PTEN PIP PIP
+ = + = + =
+ + + + =
  (A9) 
where AKTo, *3 oPI K , PTENo, and PIP2o are total concentrations of the species.  
From the relations of equilibrium states of PI3K-PIP2s (A3) and PTEN-PIP3s (A4) one 
can derive steady state concentrations of enzyme-substrate complexes PI3K-PIP2s, PTEN-
PIP3s and final complex AKT-PIP3s: 
KPIm
ss
s K
KPIPIPPIPKPI
3,
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PTENm
ss
s K
PTENPIPPIPPTEN
,
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are Michaelis constants and Kd,PI3K, Kd,PTEN, and Kd,AKT – dissociation constants. 
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Substituting equations (A10) into equilibrium relation of PIP2 (A1), one can obtain the 
relationship between steady sate concentrations of *sPI3K  , PTENs , PIP2s , and PIP3s [18] as 
, 3 ,
*
, 3 ,
2
3 3
m PI K cat PTEN s s
cat PI K s m PTEN s
K k PTEN PIP
k PI K K PIP
= .          (A11) 
Expressing the concentration of PIP3s in term of AKT-PIP3s concentration (A10) and 
using the conservation low for AKT (A9) we can rewrite relation (A11) as 
, 3 , ,
*
, 3 ,
1 12
3 - 3
m PI K cat PTEN s d AKT
s
cat PI K s m PTEN o s o
K k PTEN K
PIP
k PI K K AKT AKT PIP AKT
 
= − 
 
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Figure legends 
 
Fig. 1. Scheme of RAF/MEK/ERK and PI3K/PTEN/AKT signalling network. A subsystem of 
PI3K/PTEN/AKT cycle is marked by dotted frame. LY294002 and bpV(pic) are inhibitors of 
PI3K and PTEN, respectively. HER2, HER3 – the epidermal growth factor receptors; HRG – 
heregulin; 2C4 – pertuzumab; HER23 – HER2/HER3 heterodimer; Shc – Src-homology and 
collagen domain protein; GS – Grb2-SOS complex; PIP2 – phosphatidylinositol; PIP3 – 
phosphatidylinositol-3,4,5-trisphosphate; RAF* and PI3K* – activated RAF and PI3K 
enzymes; PP2A – protein phosphatase 2A; PDK – phosphoinositide-dependent kinase 1; 
MKP3 – MAPK phosphatase 3.  
 
Fig. 2. Kinetics of pHER2 (A), PI3K* (B), pAKT (C, D) and PIP2 (E, F) induced by 1 nM  
HRG in the absence (lines 1) and presence of 100 nM 2C4 (lines 2). D and F - pAKT and 
PIP2 kinetics, calculated in the present of PTEN inhibitor, bpV(pic) (50 nM). Concentrations 
of pHER2 and pAKT are normalized to their maximal concentrations. Lines – simulated 
kinetics, points – experimental data in the absence (filled squares) and presence of 100 nM 
pertuzumab (unfilled squares).  
 
Fig. 3. Effect of PTEN and PI3K inhibitors and their combinations on pAKT inhibition by 
pertuzumab. The theoretical pAKT dose-dependence for pertuzumab alone, γ=1 (black line); 
at the presence of PTEN inhibitor, bpV(pic) (50 nM), γ=0.3 (blue line); at the presence of 
PI3K inhibitor, LY294002 (5 µM), γ=10 (green line); at the combination of LY294002 (5 
µM)+bpV(pic) (50 nM), γ≅1, (red line). The pAKT concentration was taken at 30th min after 
HRG stimulation and normalized to its maximal concentration. The points mark the 
pertuzumab concentrations at which pAKT inhibition was measured. 
 
Fig. 4. Comparison of the theoretical and experimental data on the effects of three inhibitors, 
pertuzumab (2C4), 100 nM; bpV(pic), 50 nM; LY294002, 5 µM and their combinations on 
AKT activation. Grey and black bars – experimental and simulation data on pAKT 
concentration at 30 min after HRG stimulation, respectively (normalized to its maximal 
concentration). 
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Fig. 5. Dependence of pAKT output signal on pHER2 input signal at the different values of 
the control parameter γ: line 1 – γ=0-0.3; 2 – 0.5;  3 – 0.7; 4 – 0.8;  5 – 0.9; 6 – 1;  7 – 1.3. The 
concentrations of pHER2 and pAKT are normalized to their maximal concentrations. 
 
Fig. 6. Dependence of the resistance index R90(γ) on the control parameter γ. γ is changed by 
variation of the enzyme activities of PTEN (black line), PI3K (blue line), AKT (red line), and 
both PTEN and CK2/GSK3 (black dashed line).  
 
Fig. 7. The pAKT dose-dependences for PI3K inhibitor (LY294002) simulated in the absence 
(solid line) and presence of PTEN inhibitor, bpV(pic), 50 nM (dashed line). The point marks 
the LY294002 concentration at which pAKT inhibition was measured. pAKT concentration is 
normalized to its maximal concentration. 
 
Fig. 8. Experimental data on the correlation between the ratio γexp= tPTEN/(tPI3K⋅tAKT) and 
cell growth inhibition by pertuzumab for 13 ovarian carcinoma cell lines: OAW42, OVCAR4, 
59M, SKOV3, OVCAR5, PEA2, PE014, 42M, CAOV3, PE01, OVCAR3, PE04, PE06 [7]. 
Points – experimental data, line – regression line. 
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Supplement. Dependence of pAKT output signal on pHER2 input signal. 
 
    a 
 
          b 
Supplementary Fig. 1. Dependence of pAKT output signal on pHER2 input signal at the 
different values of the control parameter γ.  γ is changed by variation of the PI3K enzyme 
activities (a) and affinity of AKT to PIP3 (b). γ=0.1 (line 1), 0.3 (line 2), 0.5 (line 3), 0.7 (line 
4), 0.8 (line 5), 0.9 (line 6), 1 (line 7), 1.3 (line 8).  
 
 
